Battery-free, smart contact lens delivers glaucoma drugs

Article

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Early testing of a smart contact lens shows promise for treating glaucoma, according to researchers in China.

  Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

The wireless, double-layer contact lens measures intraocular pressure (IOP) by using small sensors—similar to that of a sandwich—that, when squeezed together, create an electrical signal.

When strong enough, the signal directly triggers the delivery of an anti-glaucoma drug. The drug is stored in a hydrogel layer that is within the lens and is delivered into the cornea with the aid of a weak electrical current.

The wireless, double-layer design of the contact lens creates a device that is minimally invasive, battery-free, and has the potential for large-scale production, as its manufacturing process is compatible with the commercial production of printed circuit boards, according to investigators.

The researchers recently published their findings in Nature Communications, where they reported results from testing the lens on the eyes of pigs and live rabbits.

In the rabbit experiment, the anti-glaucoma drug delivery lowered the IOP by about one-third within 30 minutes. It also helped to maintain those levels for a longer period of time when compared to delivery of the same drug via an eye drop (in which the IOP quickly bounced back).

Additional research is needed before clinical testing of the contact lens device can be done on human patients diagnosed with glaucoma.

According to researchers, the ideal device would consistently respond to fluctuations in an individual’s IOP before it ends up causing irreversible vision loss.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
In a study, a xenon slide illuminator was employed to mimic natural outdoor colors, allowing researchers to test brightness perception using a brightness-matching method, explains Billy R. Hammond.
Christi Closson, OD, FAAO, provides insight on what other ODs learned about Johnson & Johnson's contact lens technology.
Dana Shannon, OD, FAAO, details The Contact Lens Instiute's latest report, The Dropout Dilemma.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Erin Tomiyama, OD, PhD, FAAO, discusses fitting lenses, young adults with binocular vision issues, and emerging presbyopia in patients.
© 2024 MJH Life Sciences

All rights reserved.